A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B–containing lipoprotein secretion
Abstract Aims Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite th...
Uložené v:
| Vydané v: | Cardiovascular research Ročník 120; číslo 11; s. 1253 - 1264 |
|---|---|
| Hlavní autori: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
UK
Oxford University Press
21.09.2024
|
| Predmet: | |
| ISSN: | 0008-6363, 1755-3245, 1755-3245 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Abstract
Aims
Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses.
Methods and results
To facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells.
Conclusions
In summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations.
Graphical Abstract
Graphical Abstract |
|---|---|
| AbstractList | Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses.AIMSApolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses.To facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells.METHODS AND RESULTSTo facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells.In summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations.CONCLUSIONSIn summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations. Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses. To facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells. In summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations. Abstract Aims Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses. Methods and results To facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells. Conclusions In summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations. Graphical Abstract Graphical Abstract |
| Author | van den Berg, Marlene Kuivenhoven, Jan Albert Veenendaal, Tineke Tantucci, Matteo Zelcer, Noam Ndoj, Klevis Marinković, Goran Klumperman, Judith Meurs, Amber |
| Author_xml | – sequence: 1 givenname: Amber surname: Meurs fullname: Meurs, Amber – sequence: 2 givenname: Klevis surname: Ndoj fullname: Ndoj, Klevis – sequence: 3 givenname: Marlene surname: van den Berg fullname: van den Berg, Marlene – sequence: 4 givenname: Goran surname: Marinković fullname: Marinković, Goran – sequence: 5 givenname: Matteo surname: Tantucci fullname: Tantucci, Matteo – sequence: 6 givenname: Tineke surname: Veenendaal fullname: Veenendaal, Tineke – sequence: 7 givenname: Jan Albert surname: Kuivenhoven fullname: Kuivenhoven, Jan Albert – sequence: 8 givenname: Judith surname: Klumperman fullname: Klumperman, Judith – sequence: 9 givenname: Noam orcidid: 0000-0001-6935-7532 surname: Zelcer fullname: Zelcer, Noam email: n.zelcer@amsterdamumc.nl |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38833612$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkc1KxDAUhYMozvizci9ZiZtq0qRpuxzFPxDc6Lqk6c1MpE1qkw648x18El_JJzHFUQQXl3uT-3G4nLOHtq2zgNARJWeUlOxcrYdYEmhKt9Cc5lmWsJRn22hOCCkSwQSboT3vn-Mzy3K-i2asKBgTNJ2jjwX2owmAncZLsK6DBOzSWIABGryCXgajsIK29bgf3No04LF1a2ixsd4sV8HHITgcVoD9RLsAXe8G2eIOgqxda3w3qcs-jr2LIgGMxRdY2ubf5-fbu3I2SGONXeK_Kw9qgKhuD9COlq2Hw03fR0_XV4-Xt8n9w83d5eI-UZyykEQ_Cp1qJajWkNJaNFzndcNApA0ta025ElwzmUvFy1xwkjVa6AKIhOhaXbJ9dPqtGy94GcGHqjN-MkJacKOvGBG8TElGJvR4g451B03VD6aTw2v1Y3METr4BN_a_W0qqKb8q5ldt8mNfKHuViQ |
| CitedBy_id | crossref_primary_10_1016_j_molmet_2025_102137 crossref_primary_10_1016_j_phrs_2025_107603 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. 2024 The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. |
| Copyright_xml | – notice: The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. 2024 – notice: The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. |
| DBID | TOX CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/cvr/cvae121 |
| DatabaseName | Oxford Journals Open Access Collection Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1755-3245 |
| EndPage | 1264 |
| ExternalDocumentID | 38833612 10.1093/cvr/cvae121 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: GENESIS – fundername: ZonMw grantid: 09120012110057 – fundername: Dutch Research Council – fundername: EndoConnect – fundername: European Union grantid: 953489 – fundername: Netherlands Organization for Scientific Research grantid: M.22.034 – fundername: Dutch Heart Foundation grantid: 2013T111 |
| GroupedDBID | --- --K -E4 .2P .55 .GJ .I3 .ZR 08P 0R~ 18M 1B1 1TH 29B 2WC 3O- 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACZT AAGQS AAJKP AAJQQ AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT ABDFA ABEJV ABEUO ABGNP ABHFT ABIXL ABJNI ABKDP ABLJU ABNGD ABNHQ ABNKS ABOCM ABPQP ABPTD ABQLI ABQNK ABQTQ ABSMQ ABVGC ABWST ABXVV ABZBJ ACFRR ACGFO ACGFS ACPQN ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEJTW AEKPW AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFQV AFFZL AFIYH AFOFC AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMMS AHXPO AI. AIAGR AIJHB AJDVS AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVNTJ AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IHE IOX J21 J5H JXSIZ KAQDR KBUDW KOP KSI KSN L7B LMP M-Z M41 M49 MBLQV MHKGH MJL N4W N9A NGC NOMLY NOYVH NQ- NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OCZFY ODMLO OJQWA OJZSN OK1 OOVWX OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM Q1. Q5Y QBD R44 RD5 RIG ROL ROX ROZ RPZ RUSNO RW1 RXO SEL SV3 TCURE TEORI TJX TMA TOX VH1 W8F WH7 X7H X7M XPP YAYTL YKOAZ YXANX ZGI ZXP ~91 AGORE AHGBF AJBYB CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c413t-ae18f2fc61ffe21b6d4f7bd3e62d19bf14c64f3a7ac4976405df6f8e0ae008b93 |
| IEDL.DBID | TOX |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001247663000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-6363 1755-3245 |
| IngestDate | Sat Sep 27 23:31:44 EDT 2025 Sat Sep 13 02:30:34 EDT 2025 Wed Apr 02 07:03:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | ERAD Hepatocytes HRD1 VLDL SYVN1 APOB MASLD Lipoprotein metabolism |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c413t-ae18f2fc61ffe21b6d4f7bd3e62d19bf14c64f3a7ac4976405df6f8e0ae008b93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-6935-7532 |
| OpenAccessLink | https://dx.doi.org/10.1093/cvr/cvae121 |
| PMID | 38833612 |
| PQID | 3064920509 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_3064920509 pubmed_primary_38833612 oup_primary_10_1093_cvr_cvae121 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-21 |
| PublicationDateYYYYMMDD | 2024-09-21 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | UK |
| PublicationPlace_xml | – name: UK – name: England |
| PublicationTitle | Cardiovascular research |
| PublicationTitleAlternate | Cardiovasc Res |
| PublicationYear | 2024 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| SSID | ssj0005574 |
| Score | 2.4740145 |
| Snippet | Abstract
Aims
Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and... Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating... |
| SourceID | proquest pubmed oup |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1253 |
| SubjectTerms | Apolipoprotein B-100 - genetics Apolipoprotein B-100 - metabolism CRISPR-Cas Systems Endoplasmic Reticulum - metabolism Gene Editing Golgi Apparatus - metabolism Hep G2 Cells Hepatocytes - metabolism Humans Lipoproteins, VLDL - metabolism Receptors, LDL - genetics Receptors, LDL - metabolism Time Factors |
| Title | A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B–containing lipoprotein secretion |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38833612 https://www.proquest.com/docview/3064920509 |
| Volume | 120 |
| WOSCitedRecordID | wos001247663000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NTtwwELYoqqpeSkv_ti1gpF6jruPEcY5L1RUHWDgA2lvkOGOx0m6C1tk99x14kr4ST9KZxEAFSOWQKEqUUeKZ2J_jb75h7Htpc5dY9EBmUxMl1oiotGkWKRUbbVLj8o7le3GUTSZ6Os1PA0HWP7GEn8sfdr3EzYDo8sVFqqlQwdnJ9J7JkQax5aGOlFQypOE9uPdBBtsjINkNKOOt5z7KW_YmQEY-6n38jm1Avc1eHYdF8ffsz4j7FSJH3jhOkqsLiCCoDELFL4E405bTH3rPQ-Kd53Wzhjmf1Z4m5x4P2oYjFuS-Y1gHwao5X0CLUTKf-QVZN1TS4arptB1mNT_gpq4enbz5fU38977yBP_3kieISoHwgZ2Pf539PIxCJYbI4iDXRvjG2sXOKuEcxKJUVeKyspKg4krkpROJVYmTJjM2QXyDILByymkYGkCnlLn8yDbrpobPjGMPAgkVWgejE5K7y7TIDKLCIcgce-0B20M3FVe91kbRr5HLAlu-CC0_YPu3LizwW6DmMzU0K1_QbCqPSdFmwD71vr0zJKmqMsK5L_-1_5W9jhG5ECkkFt_YZrtcwQ57adftzC932YtsqnE_OT3e7cLwL0VN3pw |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+suite+of+genome-engineered+hepatic+cells+provides+novel+insights+into+the+spatiotemporal+metabolism+of+apolipoprotein+B+and+apolipoprotein+B%E2%80%93containing+lipoprotein+secretion&rft.jtitle=Cardiovascular+research&rft.au=Meurs%2C+Amber&rft.au=Ndoj%2C+Klevis&rft.au=van+den+Berg%2C+Marlene&rft.au=Marinkovi%C4%87%2C+Goran&rft.date=2024-09-21&rft.pub=Oxford+University+Press&rft.issn=0008-6363&rft.eissn=1755-3245&rft.volume=120&rft.issue=11&rft.spage=1253&rft.epage=1264&rft_id=info:doi/10.1093%2Fcvr%2Fcvae121&rft.externalDocID=10.1093%2Fcvr%2Fcvae121 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-6363&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-6363&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-6363&client=summon |